Search research articles
Contact Us
Filters
Showing results (1-10 of 10) with videos related to
Page
of 1
Sort By:
Archives of Neurology
|
December 17, 2003
Levetiracetam for phasic spasticity in multiple sclerosis
Kathleen Hawker, Elliot Frohman, Michael Racke
JAMA Neurology
|
September 1, 2015
Responsibilities of Health Care Professionals in Counseling and Educating Patients With Incurable Neurological Diseases Regarding "Stem Cell Tourism": Caveat Emptor
Michelle Bowman, Michael Racke, John Kissel, et al.
Therapeutic Advances in Neurological Disorders
|
October 20, 2011
Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis
Aaron Boster, Mary Pat Bartoszek, Colleen O'Connell, et al.
Journal of Neuroimmunology
|
December 16, 2006
Cerebrospinal fluid B cells from multiple sclerosis patients are subject to normal germinal center selection
Christopher Harp, Jane Lee, Doris Lambracht-Washington, et al.
The Neurologist
|
June 14, 2003
Disease-modifying therapy in multiple sclerosis: strategies for optimizing management
Elliot Frohman, Ted Phillips, Kristen Kokel, et al.
Neurology(R) Neuroimmunology & Neuroinflammation
|
November 10, 2022
Recurrent Optic Neuritis and Perineuritis Followed by an Unexpected Discovery: From the National Multiple Sclerosis Society Case Conference Proceedings
Daniela A Pimentel Maldonado, Robert Lisak, Steven Galetta, et al.
Journal of Clinical Immunology
|
June 17, 2022
Defining Clinical and Immunological Predictors of Poor Immune Responses to COVID-19 mRNA Vaccines in Patients with Primary Antibody Deficiency
Junghee Jenny Shin, Jennefer Par-Young, Serhan Unlu, et al.
Journal of Neurology
|
May 16, 2009
Factors that influence adherence with disease-modifying therapy in MS
Katherine Treadaway, Gary Cutter, Amber Salter, et al.
Contemporary Clinical Trials
|
August 14, 2016
Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis
Robert J Fox, Christopher S Coffey, Merit E Cudkowicz, et al.
The New England Journal of Medicine
|
August 30, 2018
Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis
Robert J Fox, Christopher S Coffey, Robin Conwit, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 10) with videos related to
Sort By:
Page
of 1
Archives of Neurology
|
December 17, 2003
Levetiracetam for phasic spasticity in multiple sclerosis
Kathleen Hawker, Elliot Frohman, Michael Racke
JAMA Neurology
|
September 1, 2015
Responsibilities of Health Care Professionals in Counseling and Educating Patients With Incurable Neurological Diseases Regarding "Stem Cell Tourism": Caveat Emptor
Michelle Bowman, Michael Racke, John Kissel, et al.
Therapeutic Advances in Neurological Disorders
|
October 20, 2011
Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis
Aaron Boster, Mary Pat Bartoszek, Colleen O'Connell, et al.
Journal of Neuroimmunology
|
December 16, 2006
Cerebrospinal fluid B cells from multiple sclerosis patients are subject to normal germinal center selection
Christopher Harp, Jane Lee, Doris Lambracht-Washington, et al.
The Neurologist
|
June 14, 2003
Disease-modifying therapy in multiple sclerosis: strategies for optimizing management
Elliot Frohman, Ted Phillips, Kristen Kokel, et al.
Neurology(R) Neuroimmunology & Neuroinflammation
|
November 10, 2022
Recurrent Optic Neuritis and Perineuritis Followed by an Unexpected Discovery: From the National Multiple Sclerosis Society Case Conference Proceedings
Daniela A Pimentel Maldonado, Robert Lisak, Steven Galetta, et al.
Journal of Clinical Immunology
|
June 17, 2022
Defining Clinical and Immunological Predictors of Poor Immune Responses to COVID-19 mRNA Vaccines in Patients with Primary Antibody Deficiency
Junghee Jenny Shin, Jennefer Par-Young, Serhan Unlu, et al.
Journal of Neurology
|
May 16, 2009
Factors that influence adherence with disease-modifying therapy in MS
Katherine Treadaway, Gary Cutter, Amber Salter, et al.
Contemporary Clinical Trials
|
August 14, 2016
Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis
Robert J Fox, Christopher S Coffey, Merit E Cudkowicz, et al.
The New England Journal of Medicine
|
August 30, 2018
Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis
Robert J Fox, Christopher S Coffey, Robin Conwit, et al.
Page
of 1